FIT is the gold standard in Colorectal Cancer detection, receiving a grade of 1B by the American College of Gastroenterology. Clinical studies have shown that the Fecal Immunochemical Test is highly sensitive for detecting human hemoglobin in and around the stool, a key indicator of abnormalities in the colon and rectum that doctors use to help screen for colorectal cancer. The test is 98% sensitive (sensitivity is defined as detecting a disease state when a disease state is in fact present) for human hemoglobin. In a study of patients who were at average risk, high risk or had no symptoms at all, The FIT test was found to have 33% greater sensitivity for colorectal cancer than a leading guaiac-based FOBT screening test. Additionally, FIT boasts a 96% specificity rating (specificity defined as the ability to produce a negative result when the disease state is not present) for dependable results.
The Fecal Immunochemical Test is the gold standard in colon cancer detection, according to the ACG. The American College of Gastroenterology (ACG) recommends that older guaiac (Hemmocult) cards be abandoned as a method for colon cancer screening and that a FIT (fecal immunochemical test) be used annually. Click here for the full ACG guidelines > FIT is a single sample point-of-care test that is CLIA waived, with no diet or medicine restrictions and feasible to be performed in the physicians office or as a test that is sent home and brought back to the doctor.